Research and Markets: Pfizers Branded Drugs Are Forecast To Capture a Substantial 41% of the Neuropathic Pain Market Share In 2016.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c72356) has announced the addition of Pipeline Insight: Neuropathic Pain - Emerging drugs fail to capitalize in lucrative market to their offering. Introduction The neuropathic pain market is forecast to double from 2006 to reach over $7 billion by 2016. At this time, the current late-stage neuropathic pain pipeline is forecast to take only 18% of the total market share, highlighting an opportunity for better pipeline drugs that demonstrate improved pain management. The most promising and closest pipeline drug to market is UCBs Vimpat (lacosamide). Scope Analysis of patient potential, unmet needs and clinical trial design in neuropathic pain Overview of drugs in late- and early-stage clinical development; with analysis of key companies involved in the market Detailed profiles of key compounds in development for use in neuropathic pain, with indication-specific drug sales forecasts to 2016 Discussion of Pfizer, Eli Lilly and UCBs market strategies and insight from key opinion leaders. Highlights UCBs increasing CNS See Continuous net settlement. CNS See continuous net settlement (CNS). portfolio is further bolstered by the imminent arrival of Vimpat on the market. CNS is a key area of investigation for UCB UCB - University of California at Berkeley , constituting 39% of their sales in 2006. UCB has further expanded its reach by trialling this anticonvulsant anticonvulsant /an·ti·con·vul·sant/ (-kon-vul´sant) inhibiting convulsions, or an agent that does this. an·ti·con·vul·sant n. A drug that prevents or relieves convulsions. not just for epilepsy but also for neuropathic pain, fibromyalgia fibromyalgia Chronic syndrome that is characterized by musculoskeletal pain, often at multiple sites. The cause is unknown. A significant number of persons with fibromyalgia also have mental disorders, especially depression. , migraine and osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. . NeurogesXs Transacin (capsaicin capsaicin /cap·sa·i·cin/ (kap-sa´i-sin) an alkaloid irritating to the skin and mucous membranes, the active ingredient of capsicum; used as a topical counterirritant and analgesic. cap·sa·i·cin n. ) treatment is set to cause a stir in the topical market, currently dominated by Endos Lidoderm (lidocaine lidocaine /li·do·caine/ (li´do-kan) an anesthetic with sedative, analgesic, and cardiac depressant properties, applied topically in the form of the base or hydrochloride salt as a local anesthetic; also used in the latter form as a 5% patch). The advantageous 3 monthly dosing regimen coupled with a strong efficacy and safety profile, will see Transacin draw favorable returns in its niche market. Pfizer will continue to be a major contender in neuropathic pain, with the current market leader Lyrica predicted to be an even greater commercial success than its predecessor Neurontin (gabapentin). Pfizers branded drugs are forecast to capture a substantial 41% of the neuropathic pain market share in 2016. Reasons to Purchase Understand unmet needs in the neuropathic pain market based on key opinion leader insight Benchmark key late-stage neuropathic pain compounds against current market leaders Assess the global (US, Japan, five major EU) sales forecasts of key late-stage pipeline drugs; and examine their clinical and commercial potential. Content Outline: About Us Healthcare About The Central Nervous System Pharmaceutical Analysis Team Chapter 1 Executive Summary Chapter 2 Pipeline Overview And Dynamics Chapter 3 Neuropathic Pain - Market Overview Chapter 4 R&D Approach Chapter 5 Glutamate Receptor Modulators Late-Stage Drug Analysis & Forecasts Chapter 6 Ion Channel ion channel n. See channel. Modulators Late-Stage Drug Analysis And Forecasts Chapter 7 GABA GABA ?. GABA abbr. gamma-aminobutyric acid GABA (gamma-aminobutyric acid) A neurotransmitter that slows down the activity of nerve cells in the brain. Modulators Late-Stage Drug Analysis And Forecasts Chapter 8 Monoamine monoamine /mono·amine/ (mon?o-ah-men´) an amine containing one amino group, e.g., serotonin, dopamine, epinephrine, and norepinephrine. mon·o·am·ine n. Modulators Late-Stage Analysis And Forecasts Chapter 9 Other Late-Stage Drug Analysis And Forecasts Chapter 10 Innovative Early-Stage Projects Bibliography Appendix A Appendix B List of Tables List of Figures For more information visit http://www.researchandmarkets.com/reports/c72356 Source: Datamonitor |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion